Table A3.
General article information regarding disease, drugs, formulation, and outcomes.
| Condition, Reference | Active Ingredients in the Polypill and Free-Pill Combination | Dose (mg) | Outcome on Adherence (+: Improved with Using FDC; −: Decreased with Using FDC; 0: No Difference) |
|---|---|---|---|
| CVD [35] | FPC and FDC: acetylsalicylic acid/simvastatin/ramipril | 100 mg/40 mg/2.5 mg or 100 mg/40 mg/5 mg or 100 mg/40 mg/10 mg | + |
| CVD [59] | FPC and FDC: aspirin/simvastatin/lisinopril/HCTZ | 75 mg/40 mg/10 mg/12.5 mg | + |
| CVD [45] | FPC: various; FDC: aspirin/simvastatin/lisinopril/either atenolol or HCTZ | 75 mg/40 mg/10 mg/ 50 mg (atenolol) or 12.5 mg (HCTZ) | + |
| CVD [48] | FPC: various; FDC: aspirin/simvastatin/lisinopril with either atenolol or HCTZ | 75 mg/40 mg/10 mg/ 50 mg (atenolol) or 12.5 mg (HCTZ) | + |
| CVD [52] | FPC: various; FDC: aspirin/simvastatin/lisinopril and either atenolol or HCTZ | 75 mg/40 mg/10 mg/ 50 mg (atenolol) or 12.5 mg (HCTZ) | + |
| CVD [61] | FPC and FDC: amlodipine/atorvastatin | FPCs: amlodipine 5 and 10 mg; atorvastatin 10, 20, 40, and 80 mg; FDCs 5 mg/10 mg or 5 mg/20 mg or 5 mg/40 mg or 5 mg/80 mg or 10 mg/10 mg or 10 mg/20 mg or 10 mg/40 mg or 10 mg/80 mg | + or − |
| Hyperlipidemia [58] | FPC and FDC: ezetimibe/statin | 10 mg/ varying dose (statin) | 0 |
| Dyslipidemia [63] | FPC: simvastatin + ezetimibe or simvastatin + niacin or lovastatin + niacin); FDC: simvastatin/ ezetimibe or simvastatin/ niacin or lovastatin/ niacin | Not mentioned | + |
| CVD [62] | FPC: niacin extended-release + lovastatin or simvastatin; FDC: niacin extended-release/ lovastatin | Not mentioned | + |
| Dyslipidemia [60] | FPC and FDC: niacin/statin | Not mentioned | + |
| CVD [49] | FPC: CCB + ACEi; FDC: amlodipine besylate/benazepril hydrochloride | Not mentioned | + |
| HT [75] | FPC: ARB + thiazide; FDC: losartan/HCTZ | FPC: not mentioned; FDC: 50 mg/12.5 mg | 0 |
| HT [66] | FPC: various; FDC: olmesartan/amlodipine/HCTZ | 20 mg/5 mg/12,5 mg or 40 mg/5 mg/12,5 mg or 40 mg/5 mg/25 mg or 40 mg/10 mg/12,5 mg or 40 mg/10 mg/25 mg | + |
| HT [73] | FPC and FDC: candesartan or valsartan or telmisartan/amlodipine | ARB (8 mg candesartan or 80 mg valsartan or 40 mg telmisartan)/5 mg amlodipine | + |
| HT [64] | FPC and FDC: ARB/thiazide diuretic or ARB/CCB | Not mentioned | + |
| HT [67] | FPC and FDC: ramipril/amlodipine or candesartan/amlodipine | Not mentioned | + |
| HT [69] | FPC and FDC: perindopril/amlodipine | Not mentioned | + |
| HT [71] | FPC and FDC: RAS inhibitor/thiazide diuretic | Not mentioned | + |
| HT [77] | FPC and FDC: various antihypertensive medicines | Not mentioned | + |
| HT [79] | FPC and FDC: ACEi or ARB/thiazide diuretic | Not mentioned | + |
| HT [74] | FPC and FDC: various antihypertensive medications | Not mentioned | + |
| HT [53] | FPC and FDC: ARB/dihydropyridine CCB | Not mentioned | + |
| HT [42] | FPC and FDC: olmesartan/amlodipine | 20 mg/5 mg or 40 mg/5 mg or 40 mg/10 mg | + |
| HT [76] | FPC and FDC: various antihypertensive drugs | Not mentioned | 0 |
| HT [5] | FPC and FDC: ARB/thiazide diuretic | Not mentioned | + |
| HT [82] | FPC: amlodipine + valsartan + hydrocholorothiazide; FDC: amlodipine/valsartan/HCTZ | Not mentioned | + |
| HT [70] | FPC and FDC: olmesartan/ amlodipine | Not mentioned | + |
| HT [78] | FPC: ARB + CCB; FDC: amlodipine/valsartan | Not mentioned | + |
| HT [80] | FPC and FDC: thiazide diuretic/either ACEi or ARB | Not mentioned | + or − |
| HT [81] | FPC and FDC: olmesartan or valsartan/HCTZ/amlodipine | Not mentioned | + |
| HT [83] | FPC: ARB or ACEi or BB + amlodipine + hydrocholorthiazide; FDC: BB/HCTZ + amlodipine or amlodipine/ARB + HCTZ or ARB/HCTZ + amlodipine or amlodipine/ACEi + HCTZ or ACEi/HCTZ + amlodipine | Not mentioned | + |
| HT [65] | FPC: ARB + CCB; FDC: valsartan/amlodipine | Not mentioned | + |
| HT [72] | FPC: CCB + statin; FDC: amlodipine/atorvastatin | Not mentioned | + |
| HT [55] | FPC: ARB + CCB or ARB + HCTZ, or ACEi + HCTZ; FDC: ARB/CCB or ARB/HCTZ, or ACEi/HCTZ | Not mentioned | + |
| HT [56] | FPC: ARB + dihydropyridine CCB; FDC: valsartan/amlodipine or amlodipine/olmesartan medoxomil | Not mentioned | + |
| HT [68] | FPC: amlodipine + another statin; FDC: amlodipine/ atorvastatin | Not mentioned | + |
| HT [41] | FPC and FDC: ARB/HCTZ or ACE-I/HCTZ or ACEi/CCB | Not mentioned | + |
| HT [33] | FPC and FDC: valsartan/HCTZ | Not mentioned | + |
| HT [39] | FPC: CCB + ACEi; FDC: amlodipine/benazepril | Not mentioned | + |
| HT [38] | FPC: CCB + ACEi; FDC: amlodipine besylate/benazepril hydrochloride | Not mentioned | + |
| HT [46] | FPC and FDC: amlodipine/atorvastatin or amlodipine/statin or atorvastatin/CCB or CCB/ statin | Not mentioned | + |
| HT [40] | FPC: CCB + ACEi; FDC: amlodipine/benazepril | Not mentioned | + |
| DMII [85] | FPC and FDC: vildagliptin/metformin | FPC: 50 mg vildagliptin + 850 mg metformin; FDC: not mentioned | + |
| DMII [86] | FPC and FDC: various oral antidiabetic drugs | Not mentioned | + |
| DMII [84] | FPC and FDC: various oral antidiabetics | Not mentioned | + |
| DMII [31] | FPC and FDC: pioglitazone/metformin | Not mentioned | + |
| DMII [51] | FPC: thiazolidinedione + sulfonurea; FDC: rosiglitazone/glimepiride | Not mentioned | + |
| DMII [36] | FPC and FDC: any 2 oral antidiabetic drugs (metformin/glyburide/rosiglitazone…) | Any market-available dose could be included. | + |
| DMII [44] | FPC and FDC: metformin/sulfonylurea | Not mentioned | + |
| DMII [54] | FPC and FDC: metformin/thiazolidinedione | 2 mg/1000 mg or 4 mg/1000 mg or 1 mg/500 mg or 2 mg/500 mg or 4 mg/500 mg | + |
| DMII [32] | FPC and FDC: glyburide/metformin | glyburide from 6 to 10 mg/day/ metformin from 893 mg to 1297 mg/day | + |
| DMII [43] | FPC and FDC: metformin/glyburide | Not mentioned | + or 0 |
| HIV [88] | FPC: lopinavir/ritonavir + zidovudine/lamivudine; FDC: zidovudine/lamivudine/abacavir | Induction phase: 150 mg lamivudine/300 mg zidovudine twice daily, 400 mg lopinavir/100 mg ritonavir twice daily. Test phase: group 2 kept the same regimen, group 1 switched to 300 mg zidovudine/600 mg lamivudine/600 mg abacavir. | + |
| HIV [90] | FPC: various; FDC: rilpivirine/emtricitabine/tenofovir disoproxil fumarate | Not mentioned | 0 |
| HIV [91] | FPC and FDC: various antiretroviral drugs | Not mentioned | + |
| HIV [34] | FPC: various; FDC: efavirenz/emtricitabine/tenofovir | Not mentioned | 0 |
| HIV [87] | FPC: tenofovir + efavirenz + either emtricitabine or lamivudine; FDC: emtricitabine/tenofovir/efavirenz | Not mentioned | + |
| HIV [30] | FPC: ritonavir-boosted protease inhibitor + two NRTIs or NNRTI + two NRTIs; FDC: efavirenz/emtricibine/tenofovir | Not mentioned | + |
| HIV [92] | FPC and FDC: various antiretroviral drugs | Not mentioned | + |
| HIV [94] | FPC and FDC: various antiretroviral drugs | Not mentioned | + |
| HIV [57] | FPC and FDC: NRTI/NNRTI/PI/CCR5-antagonist/integrase inhibitor | Not mentioned | + |
| HIV [93] | FPC and FDC: various antiretroviral drugs | Not mentioned | + |
| HIV [47] | FPC and FDC: various antiretroviral drugs | Not mentioned | + or 0 |
| HIV [50] | FPC: protease inhibitor + atazanavir or ritonavir + emtricitabine/tenofivor; FDC: efavirenz/emtricitabine/tenofovir | Not mentioned | 0 |
| HIV [37] | FPC: various antiretroviral drugs; FDC: tenofovir/emtricitabine/efavirenz | Not mentioned | + |
| HIV [89] | FPC and FDC: lamivudine/zidovudine | 150 mg/300 mg | + |
| LUTS/BPH [95] | FPC and FDC: α-blocker/antimuscarinic | Not mentioned | 0 |
FPC, free-pill combination; FDC, fixed-dose combination; HT, hypertension; CVD, cardiovascular disease; DMII, diabetes mellitus type II; HIV, human immunodeficiency virus; LUTS/BPH, lower urinary tract symptoms associated with benign prostatic hyperplasia; CCB, calcium channel blocker; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor II blocker; RAS, renin–angiotensin system; HCTZ, hydrochlorothiazide; BB, beta-blocker; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI, nonnucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; CCR5, chemokine receptor 5.